United Kingdom· GB-APID-37528511000001104
Komboglyze 2.5mg/1000mg tablets
A metformin and saxagliptin product containing saxagliptin + metformin, registered in United Kingdom by Mawdsley-Brooks & Company Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Metformin and saxagliptin is registered in 12 of 19 countries.
Countries holding a registration under ATC A10BD10 (metformin and saxagliptin), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Metformin and saxagliptin · ATC A10BD10
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Saxagliptin + Metformin
- Manufacturer
- Mawdsley-Brooks & Company Ltd
- Country
- United Kingdom (GB)
- ATC code
- A10BD10
- ATC class
- Metformin and saxagliptin
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for metformin and saxagliptin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and saxagliptin · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Metformin and saxagliptin in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKOMBOGLYZEAstraZeneca AB, Södertälje
- United StatesSaxagliptin and MetforminMylan Pharmaceuticals Inc.
- SwitzerlandKombiglyze XR
- SpainKOMBOGLYZE 2,5 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- CanadaKOMBOGLYZEASTRAZENECA CANADA INC
- FinlandKomboglyzeAstraZeneca AB
- IrelandKomboglyze 2.5 mg/1000 mg film-coated tabletsAstraZeneca AB
- IcelandKomboglyzeAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- France · Saxagliptine/Metformine Biogaran
- Iceland · Komboglyze
- Liechtenstein · Komboglyze
- Malta · Saxagliptin/Metformin Pharos
- Norway · Komboglyze
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f8a0839b-ae9e-49c8-933a-646960c01044 GET /v1/drugs/f8a0839b-ae9e-49c8-933a-646960c01044?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "37528511000001104",
"desc": "Komboglyze 2.5mg/1000mg tablets (Mawdsley-Brooks & Company Ltd)",
"form": "Oral tablet",
"vpid": "21711411000001100",
"source": "dmd",
"vtm_id": "784227008",
"strength": "2.5 mg",
"substance": "Saxagliptin + Metformin",
"ingredient": "Saxagliptin hydrochloride",
"supplier_code": "15125811000001100"
}See everything about metformin and saxagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.